ALIGNMENT HEALTHCARE INC (ALHC) Stock Fundamental Analysis
NASDAQ:ALHC - US01625V1044 - Common Stock
16.36 USD
+0.04 (+0.25%)
16.36 USD
0 (0%)
We assign a fundamental rating of 3 out of 10 to ALHC. ALHC was compared to 102 industry peers in the Health Care Providers & Services industry. ALHC may be in some trouble as it scores bad on both profitability and health. ALHC is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
ALHC had negative earnings in the past year.
ALHC had a positive operating cash flow in the past year.
In the past 5 years ALHC always reported negative net income.
In multiple years ALHC reported negative operating cash flow during the last 5 years.
1.2 Ratios
ALHC's Return On Assets of -5.09% is on the low side compared to the rest of the industry. ALHC is outperformed by 67.65% of its industry peers.
ALHC's Return On Equity of -36.14% is on the low side compared to the rest of the industry. ALHC is outperformed by 70.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.09% | ||
| ROE | -36.14% | ||
| ROIC | N/A |
ROA(3y)-21.65%
ROA(5y)-20.54%
ROE(3y)-95.11%
ROE(5y)-84.8%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ALHC has a worse Gross Margin (12.14%) than 70.59% of its industry peers.
ALHC's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for ALHC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 12.14% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.14%
GM growth 5Y-2.77%
2. Health
2.1 Basic Checks
ALHC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALHC has been increased compared to 1 year ago.
Compared to 5 years ago, ALHC has more shares outstanding
Compared to 1 year ago, ALHC has a worse debt to assets ratio.
2.2 Solvency
ALHC has an Altman-Z score of 4.54. This indicates that ALHC is financially healthy and has little risk of bankruptcy at the moment.
ALHC has a Altman-Z score of 4.54. This is in the better half of the industry: ALHC outperforms 77.45% of its industry peers.
ALHC has a debt to FCF ratio of 11.35. This is a negative value and a sign of low solvency as ALHC would need 11.35 years to pay back of all of its debts.
ALHC has a Debt to FCF ratio (11.35) which is in line with its industry peers.
ALHC has a Debt/Equity ratio of 2.29. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 2.29, ALHC is doing worse than 73.53% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.29 | ||
| Debt/FCF | 11.35 | ||
| Altman-Z | 4.54 |
ROIC/WACCN/A
WACC8.76%
2.3 Liquidity
ALHC has a Current Ratio of 1.66. This is a normal value and indicates that ALHC is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.66, ALHC is in line with its industry, outperforming 56.86% of the companies in the same industry.
ALHC has a Quick Ratio of 1.66. This is a normal value and indicates that ALHC is financially healthy and should not expect problems in meeting its short term obligations.
ALHC has a Quick ratio (1.66) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.66 | ||
| Quick Ratio | 1.66 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 66.67% over the past year.
Looking at the last year, ALHC shows a very strong growth in Revenue. The Revenue has grown by 49.46%.
The Revenue has been growing by 28.99% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)66.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%153.85%
Revenue 1Y (TTM)49.46%
Revenue growth 3Y32.29%
Revenue growth 5Y28.99%
Sales Q2Q%49.03%
3.2 Future
ALHC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.00% yearly.
Based on estimates for the next years, ALHC will show a very strong growth in Revenue. The Revenue will grow by 26.80% on average per year.
EPS Next Y72.09%
EPS Next 2Y43.68%
EPS Next 3Y34.73%
EPS Next 5Y33%
Revenue Next Year45.64%
Revenue Next 2Y36.78%
Revenue Next 3Y32.73%
Revenue Next 5Y26.81%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ALHC. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 379.90, the valuation of ALHC can be described as expensive.
Based on the Price/Forward Earnings ratio, ALHC is valued a bit more expensive than 61.76% of the companies in the same industry.
ALHC's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.76.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 379.9 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ALHC is valued a bit more expensive than the industry average as 64.71% of the companies are valued more cheaply.
ALHC's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 114.05 | ||
| EV/EBITDA | 594.26 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ALHC does not grow enough to justify the current Price/Earnings ratio.
ALHC's earnings are expected to grow with 34.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.68%
EPS Next 3Y34.73%
5. Dividend
5.1 Amount
No dividends for ALHC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
16.36
+0.04 (+0.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners68.79%
Inst Owner Change2.48%
Ins Owners4.61%
Ins Owner Change19.36%
Market Cap3.24B
Analysts83.33
Price Target19.49 (19.13%)
Short Float %9.33%
Short Ratio3.93
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)128.24%
Min EPS beat(2)61.17%
Max EPS beat(2)195.32%
EPS beat(4)4
Avg EPS beat(4)69.56%
Min EPS beat(4)3.21%
Max EPS beat(4)195.32%
EPS beat(8)6
Avg EPS beat(8)34.1%
EPS beat(12)9
Avg EPS beat(12)28.2%
EPS beat(16)12
Avg EPS beat(16)24.17%
Revenue beat(2)2
Avg Revenue beat(2)2.98%
Min Revenue beat(2)2.3%
Max Revenue beat(2)3.66%
Revenue beat(4)4
Avg Revenue beat(4)2.52%
Min Revenue beat(4)1.59%
Max Revenue beat(4)3.66%
Revenue beat(8)8
Avg Revenue beat(8)2.72%
Revenue beat(12)11
Avg Revenue beat(12)2.9%
Revenue beat(16)15
Avg Revenue beat(16)3.49%
PT rev (1m)2.99%
PT rev (3m)4.01%
EPS NQ rev (1m)0.96%
EPS NQ rev (3m)6.41%
EPS NY rev (1m)46.95%
EPS NY rev (3m)47.05%
Revenue NQ rev (1m)1.43%
Revenue NQ rev (3m)11.8%
Revenue NY rev (1m)2.63%
Revenue NY rev (3m)2.95%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 379.9 | ||
| P/S | 0.97 | ||
| P/FCF | 114.05 | ||
| P/OCF | 51.24 | ||
| P/B | 22.98 | ||
| P/tB | 31.05 | ||
| EV/EBITDA | 594.26 |
EPS(TTM)-0.27
EYN/A
EPS(NY)0.04
Fwd EY0.26%
FCF(TTM)0.14
FCFY0.88%
OCF(TTM)0.32
OCFY1.95%
SpS16.85
BVpS0.71
TBVpS0.53
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.09% | ||
| ROE | -36.14% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 12.14% | ||
| FCFM | 0.85% |
ROA(3y)-21.65%
ROA(5y)-20.54%
ROE(3y)-95.11%
ROE(5y)-84.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.14%
GM growth 5Y-2.77%
F-Score6
Asset Turnover3.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.29 | ||
| Debt/FCF | 11.35 | ||
| Debt/EBITDA | 63.32 | ||
| Cap/Depr | 119.42% | ||
| Cap/Sales | 1.04% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 1242.14% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.66 | ||
| Quick Ratio | 1.66 | ||
| Altman-Z | 4.54 |
F-Score6
WACC8.76%
ROIC/WACCN/A
Cap/Depr(3y)151.69%
Cap/Depr(5y)136.01%
Cap/Sales(3y)1.72%
Cap/Sales(5y)1.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%153.85%
EPS Next Y72.09%
EPS Next 2Y43.68%
EPS Next 3Y34.73%
EPS Next 5Y33%
Revenue 1Y (TTM)49.46%
Revenue growth 3Y32.29%
Revenue growth 5Y28.99%
Sales Q2Q%49.03%
Revenue Next Year45.64%
Revenue Next 2Y36.78%
Revenue Next 3Y32.73%
Revenue Next 5Y26.81%
EBIT growth 1Y81.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year161.57%
EBIT Next 3Y56.77%
EBIT Next 5YN/A
FCF growth 1Y-42.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.15%
OCF growth 3YN/A
OCF growth 5Y30.43%